Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Weiss GJ. Cost-effectiveness of capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer in the United States. PLoS One. 2026; 21(10):e0353373.
-
Zweegman S, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Marti J, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Liu W, Wang J, van Brummelen E, Krevvata M, Lopez-Masi L, Carey J, Borgsten F, Rowe M, Carson R, Usmani SZ. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood Adv. 2026 08 25; 10(16):5594-5606.
-
Facon T, Kumar SK, Orlowski RZ, Bahlis N, Moreau P, Goldschmidt H, Basu S, Hulin C, Zweegman S, Weisel K, Perrot A, Jacquet C, Raje N, Manier S, Chari A, Hansson M, Mohty M, Delforge M, Plesner T, Cook G, Leleu X, Quach H, Venner CP, Tiab M, Macro M, Frenzel L, Wang G, Pei H, Bolyard K, Carson R, Borgsten F, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. Leukemia. 2026 Nov; 40(11):2530-2539.
-
Tan CR, Gordan L, Richter J, DiLeo R, Mewawalla P, Larson S, Davies F, Oveisi D, Gupta-Werner N, Medhekar R, Yin X, Cortoos A, Armoon M, Thompson-Leduc P, Rahman A, Tardif-Samson A, Vanden Eynde C, Reitan J, Milkovich G, Bubalo J, Forman A, Bryan B, Sborov D, Kaila S, Usmani S. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future Oncol. 2026 Aug; 22(18):2169-2177.
-
Bahlis N, Facon T, San-Miguel J, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje N, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel K, Mohty M, Leleu X, Plesner T, Jakubowiak A, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK. Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026 07 14; 10(13):4541-4550.
-
Mina R, Terpos E, Cani L, Nooka A, Trudel S, Voorhees P, Mian H, Dhakal B, Usmani S, Richter J, Popat R, Mateos MV, Lonial S. Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management. Clin Lymphoma Myeloma Leuk. 2026 Sep; 26(9):609-622.
-
Roboz GJ, Zeidan AM, Mannis GN, Montesinos P, Arnan M, Savona MR, Odenike O, McCloskey JK, Amin HV, Fathi AT, Bernal Del Castillo T, Rodríguez-Macías G, Liesveld JL, Im AP, Cerny J, Gentile TC, Oganesian A, Chan D, Wan Y, Dijkstra M, Keer HN, Griffiths EA, DiNardo CD. All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. N Engl J Med. 2026 Jun 04; 394(21):2107-2116.
-
Garrido-Castro AC, Graham N, Li KX, Bi L, Crowdis J, Bi K, Park J, Pastorello R, Li Y, Gupta H, Kuntz T, Petry R, Pasquina LW, Patel A, Lange P, DiLullo M, Attaya V, Frey AM, Childress MA, Wesolowski R, Sinclair N, Sinclair S, Lo S, Tung N, Faggen M, Kaufman PA, Block CC, Walsh J, Toke M, Chen W, Wucherpfennig KW, Tian Y, Williams AJ, Mukhopadhyay S, Dasgupta T, Schnitt S, Cherniack AD, Barroso R, Ligibel J, Lin NU, Mittendorf EA, Tayob N, Van Allen E, Tolaney SM. Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial. Nat Commun. 2026 May 16; 17(1).
-
Maclachlan KH, Tan CR, Shekarkhand T, Rueda C, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz M, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone R, Jurgens EM, Miller KC, Rajeeve S, Giralt S, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ. IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM. Blood Adv. 2026 Apr 28; 10(8):2616-2625.
-
Suzuki K, Matsumoto M, Takamatsu H, Kosugi H, Kondo T, Fujisaki T, Facon T, Zweegman S, Ito M, Sakai C, Kanai S, Nakatogawa T, Rowe M, Carson R, Usmani SZ. Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial. Int J Hematol. 2026 Jul; 124(1):104-113.